CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)

Published:2022-08-30 Issue:4 Volume:50 Page:
ISSN:1107-3756
Container-title:International Journal of Molecular Medicine
language:
Short-container-title:Int J Mol Med

Author:

Huang Jinyao¹,Zheng Liang¹,Sun Zicheng²,Li Jie²

Affiliation:

1. Department of Breast and Thyroid Surgery, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China

2. Department of Breast and Thyroid Surgery, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623, P.R. China

Publisher

Spandidos Publications

Subject

Genetics,General Medicine

Reference100 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Breast cancer intrinsic subtype classification, clinical use and future trends;Dai;Am J Cancer Res,2015

3. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Ann Oncol,2017

4. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions;Milani;World J Clin Oncol,2014

5. Endocrine resistance in breast cancer-an overview and update;Clarke;Mol Cell Endocrinol,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Oncology;2024-09

2. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study;ESMO Open;2024-09

3. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia;Journal of Personalized Medicine;2024-08-23

5. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study;Cancers;2024-08-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3